{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:16:05Z","timestamp":1789636565854,"version":"4.0.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ejmech.2019.111722","type":"journal-article","created":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T19:07:44Z","timestamp":1568920064000},"page":"111722","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Discovery of novel, potent, isosteviol-based antithrombotic agents"],"prefix":"10.1016","volume":"183","author":[{"given":"Peng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko P.Y.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipra","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9605-0085","authenticated-orcid":false,"given":"Hongzheng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.111722_bib1","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1016\/j.amepre.2009.12.017","article-title":"Venous thromboembolism: a public health concern","volume":"38","author":"Beckman","year":"2010","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.ejmech.2019.111722_bib2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/jce.12891","article-title":"Stroke risk stratification in atrial fibrillation: bridging the evidence gaps","volume":"27","author":"Turakhia","year":"2016","journal-title":"J.\u00a0Cardiovasc. Electrophysiol."},{"key":"10.1016\/j.ejmech.2019.111722_bib3","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","article-title":"Global burden of thrombosis: epidemiologic aspects","volume":"118","author":"Wendelboe","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejmech.2019.111722_bib4","first-page":"525","article-title":"The perioperative management of treatment with anticoagulants and platelet aggregation inhibitors","volume":"110","author":"Schlitt","year":"2013","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.ejmech.2019.111722_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5482\/HAMO-14-12-0080","article-title":"Individualized antithrombotic therapy","volume":"36","author":"Luscher","year":"2016","journal-title":"H\u00e4mostaseologie"},{"key":"10.1016\/j.ejmech.2019.111722_bib6","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/09537104.2018.1445839","article-title":"Clinical utility of remote platelet function measurement using P-selectin: assessment of aspirin, clopidogrel, and prasugrel and bleeding disorders","volume":"29","author":"Bath","year":"2018","journal-title":"Platelets"},{"key":"10.1016\/j.ejmech.2019.111722_bib7","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.3748\/wjg.v19.i11.1673","article-title":"Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy","volume":"19","author":"Iwamoto","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2019.111722_bib8","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1038\/ki.2008.613","article-title":"Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings","volume":"Suppl","author":"Zakarija","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejmech.2019.111722_bib9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5482\/ha-1153","article-title":"Anticoagulants. Old and new","volume":"31","author":"Levi","year":"2011","journal-title":"H\u00e4mostaseologie"},{"key":"10.1016\/j.ejmech.2019.111722_bib10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nrcardio.2013.158","article-title":"Mechanical antithrombotic intervention by LAA occlusion in atrial fibrillation","volume":"10","author":"Yu","year":"2013","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejmech.2019.111722_bib11","doi-asserted-by":"crossref","first-page":"9538","DOI":"10.3390\/nu7115479","article-title":"New insights into the pros and cons of the clinical use of vitamin K antagonists (VKAs) versus direct oral anticoagulants (DOACs)","volume":"7","author":"van Gorp","year":"2015","journal-title":"Nutrients"},{"key":"10.1016\/j.ejmech.2019.111722_bib12","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1160\/TH14-11-0982","article-title":"Reversal of anticoagulants: an overview of current developments","volume":"113","author":"Greinacher","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejmech.2019.111722_bib13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1538-7836.2007.02473.x","article-title":"Factor Xa or thrombin: is factor Xa a better target?","volume":"5","author":"Ansell","year":"2007","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.ejmech.2019.111722_bib14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrd3185","article-title":"The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor","volume":"10","author":"Perzborn","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2019.111722_bib15","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2125.2012.04369.x","article-title":"Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects","volume":"75","author":"Frost","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.111722_bib16","first-page":"68","article-title":"A\u00a0randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT)","volume":"101","author":"Gretler","year":"2017","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejmech.2019.111722_bib17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/1074248414523675","article-title":"Edoxaban: review of pharmacology and key phase I to III clinical trials","volume":"19","author":"Plitt","year":"2014","journal-title":"J.\u00a0Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2019.111722_bib18","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.jcin.2014.06.014","article-title":"Direct oral anticoagulants: new drugs and new concepts","volume":"7","author":"Levy","year":"2014","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.ejmech.2019.111722_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2019.111722_bib20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2019.111722_bib21","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1021\/jm100146h","article-title":"Factor Xa inhibitors: next-generation antithrombotic agents","volume":"53","author":"Pinto","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111722_bib22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11239-014-1121-2","article-title":"A\u00a0validated high-throughput UHPLC-MS\/MS assay for accurate determination of rivaroxaban in plasma sample","volume":"39","author":"Iqbal","year":"2014","journal-title":"J.\u00a0Thromb. Thrombolysis"},{"key":"10.1016\/j.ejmech.2019.111722_bib23","article-title":"Bleeding risk and mortality of edoxaban: a pooled meta-analysis of randomized controlled trials","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2019.111722_bib24","first-page":"343","article-title":"Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism","volume":"11","author":"Chan","year":"2015","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ejmech.2019.111722_bib25","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1021\/jm801141f","article-title":"Fluorinated benzyloxyphenyl piperidine-4-carboxamides with dual function against thrombosis: inhibitors of factor Xa and platelet aggregation","volume":"52","author":"de Candia","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111722_bib26","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.ejmech.2011.03.016","article-title":"Dual anticoagulant\/antiplatelet persulfated small molecules","volume":"46","author":"Correia-da-Silva","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111722_bib27","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1021\/jm2006589","article-title":"Polysulfated xanthones: multipathway development of a new generation of dual anticoagulant\/antiplatelet agents","volume":"54","author":"Correia-da-Silva","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111722_bib28","doi-asserted-by":"crossref","first-page":"630482","DOI":"10.1155\/2015\/630482","article-title":"Polysulfated trehalose as a novel anticoagulant agent with dual mode of action","volume":"2015","author":"Rashid","year":"2015","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ejmech.2019.111722_bib29","doi-asserted-by":"crossref","first-page":"7934","DOI":"10.1038\/s41598-017-08330-1","article-title":"Evaluation of novel factor Xa inhibitors from Oxya chinensis sinuosa with anti-platelet aggregation activity","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2019.111722_bib30","first-page":"3","article-title":"Platelet-targeted dual pathway antithrombotic inhibits thrombosis with preserved hemostasis","author":"Hanjaya-Putra","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejmech.2019.111722_bib31","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed multiple ligands. An emerging drug discovery paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111722_bib32","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1021\/jm8003448","article-title":"3,4-Dihydro-2H-1,4-benzoxazine derivatives combining thrombin inhibitory and glycoprotein IIb\/IIIa receptor antagonistic activity as a novel class of antithrombotic compounds with dual function","volume":"51","author":"Ilas","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111722_bib33","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.biotechadv.2015.08.001","article-title":"Discovery and resupply of pharmacologically active plant-derived natural products: a review","volume":"33","author":"Atanasov","year":"2015","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ejmech.2019.111722_bib34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1039\/C3NP70063A","article-title":"Natural products as starting points for the synthesis of complex and diverse compounds","volume":"31","author":"Morrison","year":"2014","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.ejmech.2019.111722_bib35","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1021\/jm300288g","article-title":"Charting, navigating, and populating natural product chemical space for drug discovery","volume":"55","author":"Lachance","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111722_bib36","doi-asserted-by":"crossref","first-page":"9334","DOI":"10.1021\/acs.jmedchem.5b01329","article-title":"Phosphonooxymethyl prodrug of triptolide: synthesis, physicochemical characterization, and efficacy in human colon adenocarcinoma and ovarian cancer xenografts","volume":"58","author":"Patil","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111722_bib37","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1021\/acs.jmedchem.6b00748","article-title":"Mitragynine\/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit beta-arrestin-2","volume":"59","author":"Varadi","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111722_bib38","doi-asserted-by":"crossref","first-page":"10242","DOI":"10.1021\/acs.joc.6b01185","article-title":"Synthesis of an iridoid-inspired compound collection and discovery of autophagy inhibitors","volume":"81","author":"Schroder","year":"2016","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2019.111722_bib39","doi-asserted-by":"crossref","first-page":"7442","DOI":"10.1021\/jm401007p","article-title":"Natural product derived antiprotozoal agents: synthesis, biological evaluation, and structure-activity relationships of novel chromene and chromane derivatives","volume":"56","author":"Harel","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111722_bib40","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1021\/np50033a007","article-title":"A\u00a0phytochemical screening procedure for sweet ent-kaurene glycosides in the genus Stevia","volume":"47","author":"Kinghorn","year":"1984","journal-title":"J.\u00a0Nat. Prod."},{"key":"10.1016\/j.ejmech.2019.111722_bib41","doi-asserted-by":"crossref","first-page":"12453","DOI":"10.1021\/ja072447e","article-title":"16-Aza-ent-beyerane and 16-Aza-ent-trachylobane: potent mechanism-based inhibitors of recombinant ent-kaurene synthase from Arabidopsis thaliana","volume":"129","author":"Roy","year":"2007","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2019.111722_bib42","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.phymed.2011.01.024","article-title":"Ent-16beta,17-dihydroxy-kauran-19-oic acid, a kaurane diterpene acid from Siegesbeckia pubescens, presents antiplatelet and antithrombotic effects in rats","volume":"18","author":"Wang","year":"2011","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2019.111722_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085120","article-title":"Glaucocalyxin A inhibits platelet activation and thrombus formation preferentially via GPVI signaling pathway","volume":"8","author":"Li","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2019.111722_bib44","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ejmech.2018.07.052","article-title":"Diterpenoid lead stevioside and its hydrolysis products steviol and isosteviol: biological activity and structural modification","volume":"156","author":"Wang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111722_bib45","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.bmc.2009.01.017","article-title":"Stereoselective synthesis of bioactive isosteviol derivatives as alpha-glucosidase inhibitors","volume":"17","author":"Wu","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111722_bib46","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1016\/j.bmc.2009.07.029","article-title":"Microbial transformation of isosteviol oxime and the inhibitory effects on NF-kappaB and AP-1 activation in LPS-stimulated macrophages","volume":"17","author":"Chang","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111722_bib47","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejmech.2013.04.044","article-title":"Design and stereoselective synthesis of novel isosteviol-fused pyrazolines and pyrazoles as potential anticancer agents","volume":"65","author":"Zhu","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111722_bib48","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1016\/j.bmcl.2004.05.033","article-title":"Parallel synthesis and structure-activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitors","volume":"14","author":"Bauer","year":"2004","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2019.111722_bib49","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1039\/c005066k","article-title":"Acyclic triaryl olefins possessing a sulfohydroxamic acid pharmacophore: synthesis, nitric oxide\/nitroxyl release, cyclooxygenase inhibition, and anti-inflammatory studies","volume":"8","author":"Huang","year":"2010","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2019.111722_bib50","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10593-008-0110-9","article-title":"Oximes of five-membered heterocyclic compounds with three and four heteroatoms. Part 2. Synthesis of derivatives, reactions, and biological activity","volume":"44","author":"Abele","year":"2008","journal-title":"Chem. Heterocycl. Comp."},{"key":"10.1016\/j.ejmech.2019.111722_bib51","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2019.111722_bib52","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.beha.2004.03.002","article-title":"Platelet ADP receptor antagonists: ticlopidine and clopidogrel","volume":"17","author":"Jacobson","year":"2004","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.ejmech.2019.111722_bib53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0014-2999(96)00107-0","article-title":"Thrombin inhibitory and clot-specific fibrinolytic activities of the urokinase variant, M23 (rscu-PA-40 kDa\/Hir)","volume":"302","author":"Schneider","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.111722_bib54","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejphar.2012.04.037","article-title":"Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis","volume":"686","author":"Kalaska","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.111722_bib55","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s13361-013-0577-1","article-title":"Structural characterization of chlorophyll-a by high resolution tandem mass spectrometry","volume":"24","author":"Wei","year":"2013","journal-title":"J.\u00a0Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.ejmech.2019.111722_bib56","doi-asserted-by":"crossref","first-page":"8863","DOI":"10.1021\/ac3022778","article-title":"Structural characterization of polyketides using high mass accuracy tandem mass spectrometry","volume":"84","author":"Wills","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejmech.2019.111722_bib57","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1002\/rcm.7391","article-title":"Extensive fragmentation of pheophytin-a by infrared multiphoton dissociation tandem mass spectrometry","volume":"29","author":"Wei","year":"2015","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.ejmech.2019.111722_bib58","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relation between the inhibition constant K1) and the concentration of inhibitor which causes fifty per cent inhibition (I50) of an enzymic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.111722_bib59","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/194927b0","article-title":"Aggregation of blood platelets by adenosine diphosphate and its reversal","volume":"194","author":"Born","year":"1962","journal-title":"Nature"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419308748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419308748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:06:10Z","timestamp":1759327570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419308748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":59,"alternative-id":["S0223523419308748"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.111722","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel, potent, isosteviol-based antithrombotic agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.111722","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111722"}}